This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Development (pericardium)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

During the third week of fetal life, the mesoderm of the septum transversum at the cranial end of the embryo reorganises to give a distinct cavity, the pericardial coelom. The lining of this cavity is primitive fibrous pericardium.

Mesenchymal cells aggregate in the ventral part of the cavity to form the the primitive heart tube. The tube is attached dorsally to the wall of the cavity by a double investing layer of dorsal mesocardium. The latter is the progenitor of the serous mesocardium.

The dorsal mesocardium applies itself to the surfaces of the heart and the roots of the great vessels as they from and reposition during development. Eventually, the dorsal mesocardium degenerates from its dorsal attachments apart from the points at which it sheaths the passage of the great vessels to and from the heart and some connections between these regions. The area of dorsal mesentery loss from between the veins - pulmonary and vena cavae - and arteries - aorta and pulmonary artery - is termed the transverse sinus. The oblique sinus is formed from dorsal mesentery loss between the pulmonary veins.


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.